The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: A Randomized Phase 2/3 Multi-Center Study of SM-88 in Patients With Metastatic Pancreatic Cancer
Official Title: A Randomized Phase 2/3 Multi-Center Study of SM-88 in Subjects With Pancreatic Cancer Whose Disease Has Progressed or Recurred
Study ID: NCT03512756
Brief Summary: A prospective, open-label phase 2/3 trial in metastatic pancreatic cancer subjects who have failed two lines of prior systemic therapy. The trial is designed to evaluate the safety and efficacy of SM-88 used with MPS (methoxsalen, phenytoin and sirolimus) in pancreatic cancer and will measure multiple endpoints, including overall survival, progression free survival, relevant biomarkers, quality of life, safety, and overall response rate. (Part 1 enrollment complete) In the initial stage of the trial (36 subjects), two dose levels of SM-88's metyrosine-derivative was evaluated. (Part 2 actively enrolling) The second part will consist of a subsequent expansion of the trial to further assess safety and efficacy of SM-88 used with MPS containing the selected SM-88 RP2D from Part 1. A total of 250 subjects in the second part will be randomized 1:1 either to the SM-88 arm (125 subjects) or Physician's Choice of therapy for the Control Arm (125 subjects). Subjects should have previously received two lines of prior systemic therapy.
Detailed Description: Please refer to Inclusion/Exclusion Criteria and Summary
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
University of Alabama at Birmingham, Birmingham, Alabama, United States
City Of Hope, Duarte, California, United States
Sarcoma Oncology Research Center, Santa Monica, California, United States
Hartford Healthcare Cancer, New Britain, Connecticut, United States
H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
Advent Health Florida Hospital Tampa, Tampa, Florida, United States
June E. Nylen Cancer Center, Sioux City, Iowa, United States
University Medical Center, New Orleans, Louisiana, United States
Karmanos Cancer Institute, Detroit, Michigan, United States
Washington University, Saint Louis, Missouri, United States
New York Cancer and Blood Specialist, Bronx, New York, United States
North Shore Hematology Oncology, East Setauket, New York, United States
NY Cancer and Blood Specialist, East Setauket, New York, United States
NYU Langone Health, New York, New York, United States
Central Park Hematology & Oncology, New York, New York, United States
Weill Cornell, New York, New York, United States
The Ohio State University, Columbus, Ohio, United States
Texas Oncology-Baylor, Dallas, Texas, United States
MD Anderson, Houston, Texas, United States
Virginia Mason Medical Center, Seattle, Washington, United States
Name: Giuseppe DelPriore, MD, MPH
Affiliation: Tyme, Inc
Role: STUDY_DIRECTOR